Frontiers in Cell and Developmental Biology (Jul 2023)
Organoids: opportunities and challenges of cancer therapy
- Xianjie Jiang,
- Xianjie Jiang,
- Linda Oyang,
- Linda Oyang,
- Qiu Peng,
- Qiu Peng,
- Qiang Liu,
- Qiang Liu,
- Xuemeng Xu,
- Xuemeng Xu,
- Nayiyuan Wu,
- Nayiyuan Wu,
- Shiming Tan,
- Wenjuan Yang,
- Yaqian Han,
- Yaqian Han,
- Jinguan Lin,
- Longzheng Xia,
- Mingjing Peng,
- Mingjing Peng,
- Yanyan Tang,
- Yanyan Tang,
- Xia Luo,
- Xia Luo,
- Min Su,
- Min Su,
- Yingrui Shi,
- Yingrui Shi,
- Yujuan Zhou,
- Yujuan Zhou,
- Qianjin Liao,
- Qianjin Liao
Affiliations
- Xianjie Jiang
- Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China
- Xianjie Jiang
- Public Service Platform of Tumor Organoids Technology, Changsha, Hunan, China
- Linda Oyang
- Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China
- Linda Oyang
- Public Service Platform of Tumor Organoids Technology, Changsha, Hunan, China
- Qiu Peng
- Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China
- Qiu Peng
- Public Service Platform of Tumor Organoids Technology, Changsha, Hunan, China
- Qiang Liu
- Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China
- Qiang Liu
- Public Service Platform of Tumor Organoids Technology, Changsha, Hunan, China
- Xuemeng Xu
- Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China
- Xuemeng Xu
- Hengyang Medical School, University of South China, Hengyang, Hunan, China
- Nayiyuan Wu
- Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China
- Nayiyuan Wu
- Public Service Platform of Tumor Organoids Technology, Changsha, Hunan, China
- Shiming Tan
- Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China
- Wenjuan Yang
- Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China
- Yaqian Han
- Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China
- Yaqian Han
- Public Service Platform of Tumor Organoids Technology, Changsha, Hunan, China
- Jinguan Lin
- Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China
- Longzheng Xia
- Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China
- Mingjing Peng
- Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China
- Mingjing Peng
- Public Service Platform of Tumor Organoids Technology, Changsha, Hunan, China
- Yanyan Tang
- Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China
- Yanyan Tang
- Public Service Platform of Tumor Organoids Technology, Changsha, Hunan, China
- Xia Luo
- Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China
- Xia Luo
- Public Service Platform of Tumor Organoids Technology, Changsha, Hunan, China
- Min Su
- Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China
- Min Su
- Public Service Platform of Tumor Organoids Technology, Changsha, Hunan, China
- Yingrui Shi
- Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China
- Yingrui Shi
- Public Service Platform of Tumor Organoids Technology, Changsha, Hunan, China
- Yujuan Zhou
- Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China
- Yujuan Zhou
- Public Service Platform of Tumor Organoids Technology, Changsha, Hunan, China
- Qianjin Liao
- Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China
- Qianjin Liao
- Public Service Platform of Tumor Organoids Technology, Changsha, Hunan, China
- DOI
- https://doi.org/10.3389/fcell.2023.1232528
- Journal volume & issue
-
Vol. 11
Abstract
Organoids are a class of multicellular structures with the capability of self-organizing and the characteristic of original tissues, they are generated from stem cells in 3D culture in vitro. Organoids can mimic the occurrence and progression of original tissues and widely used in disease models in recent years. The ability of tumor organoids to retain characteristic of original tumors make them unique for tumorigenesis and cancer therapy. However, the history of organoid development and the application of organoid technology in cancer therapy are not well understood. In this paper, we reviewed the history of organoids development, the culture methods of tumor organoids establishing and the applications of organoids in cancer research for better understanding the process of tumor development and providing better strategies for cancer therapy. The standardization of organoids cultivation facilitated the large-scale production of tumor organoids. Moreover, it was found that combination of tumor organoids and other cells such as immune cells, fibroblasts and nervous cells would better mimic the microenvironment of tumor progression. This might be important developing directions for tumor organoids in the future.
Keywords
